Come up with a name for your new list and we'll add to it:
Halo Therapeutics raised a round of funding on November 14, 2013. Investors include
MDA Venture Philanthropy.
Halo Therapeutics is dedicated to the rapid development of breakthrough treatments for Duchenne muscular dystrophy (DMD) and other rare fibrotic diseases. HT-100, our initial product candidate, is ba…